In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

被引：143

作者：

Perea, S

Gonzalez, G

Fothergill, AW

Kirkpatrick, WR

Rinaldi, MG

Patterson, TF

机构：

[1] Univ Texas, Hlth Sci Ctr, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA

[2] Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA

[3] Audie Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 09期

关键词：

D O I：

10.1128/AAC.46.9.3039-3041.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The interaction between caspofungin acetate and voriconazole was studied in vitro by using 48 clinical Aspergillus spp. isolates obtained from patients with invasive aspergillosis. MICs were determined by the NCCLS broth microdilution method. Synergy, defined as a fractional inhibitory concentration (FIC) index of < 1, was detected in 87.5% of the interactions; an additive effect, defined as an FIC index of 1.0, was observed in 4.2% of the interactions; and a subadditive effect, defined as an FIC index of 1.0 to 2.0, was found in 8.3% of the interactions. No antagonism was observed. Animal models are required to validate the in vivo significance of these in vitro data presented for the combination of caspofungin and voriconazole.

引用

收藏

页码：3039 / 3041

页数：3

相关论文

共 17 条

[1] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis [J].

Abruzzo, GK ;

Flattery, AM ;

Gill, CJ ;

Kong, L ;

Smith, JG ;

Pikounis, VB ;

Balkovec, JM ;

Bouffard, AF ;

Dropinski, JF ;

Rosen, H ;

Kropp, H ;

Bartizal, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2333-2338

[2] In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :327-330

[3]

ARIKAN S, AGENTS CHEMOTHER, V46, P245

[4] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[5] In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds [J].

DelPoeta, M ;

Schell, WA ;

Perfect, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1835-1836

[6] Invasive aspergillosis [J].

Denning, DW .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :781-803

[7] In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202

[8] Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation [J].

Espinel-Ingroff, A ;

Bartlett, M ;

Chaturvedi, V ;

Ghannoum, M ;

Hazen, KC ;

Pfaller, MA ;

Rinaldi, M ;

Walsh, TJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1828-1835

[9] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[10]

Koneman E W., 1992, Diagnostic microbiology, P609